Xavier Saelens

This study expands a modular cloning platform to enable rapid, customizable construct assembly for MAPPIT assays, demonstrating its application in studying multiple protein-protein interactions.

The study shows that cross-reactive antibodies, not cross-inhibiting ones, are responsible for broad protection against heterologous HxN2 influenza viruses.

This paper describes the generation of a mouse-adapted influenza B virus strain that gains pathogenicity in mice through mutations in non-HA/NA gene segments, independent of hemagglutinin and neuraminidase.

The paper develops a targeted LC-MS method to quantify SARS-CoV-2 spike protein expression and enables proteome profiling of infected cells.

This paper designs chimeric influenza hemagglutinins that combine antigenic surfaces from different strains to elicit cross-group immunity and neutralize multiple strains.

The paper evaluates the antigenic evolution of N1 neuraminidase in H1N1 influenza viruses from 2009 to 2020, identifying key mutations driving antigenic changes and their impact on antibody neutralization.

This paper introduces GLOVID, a biosensor platform that detects intact respiratory viruses by reconstituting split luciferase, achieving ultrasensitive detection of influenza A and RSV.

This study identifies Fc-dependent protective antibodies against influenza A virus neuraminidase, showing that epitope availability and Fc-mediated effector functions influence their efficacy.

This study develops a nanoparticle vaccine displaying conserved influenza HA epitopes, inducing broad neutralizing antibodies against multiple viral subtypes.

This paper presents a yeast-based platform for producing stable and potent heavy chain-only antibodies, demonstrating its effectiveness with an anti-SARS-CoV-2 example.

This study identifies optimal sites for introducing N-glycans on VHH antibodies to enhance macrophage delivery, demonstrating glycan-dependent uptake in vitro and in vivo.

The paper describes the development of a broadly neutralizing antibody, XVR011, effective against SARS-CoV-2 and its variants in animal models.